Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome by Manders, P. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/97526
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Young age and a positive family history of colorectal cancer
are complementary selection criteria for the identification
of Lynch syndrome
P. Manders a, L. Spruijt a, C.M. Kets a, H.W. Willems b, D. Bodmer a, K.M. Hebeda b,
I.D. Nagtegaal b, J.H.J.M. van Krieken b, M.J.L. Ligtenberg a,b, N. Hoogerbrugge a,*
a Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
b Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
A R T I C L E I N F O
Article history:
Received 7 September 2010
Received in revised form 16
December 2010
Accepted 22 December 2010
Available online 25 January 2011
Keywords:
Colorectal cancer
HNPCC
Lynch syndrome
MSI testing
Bethesda criteria
Family history
A B S T R A C T
Families at high risk for Lynch syndrome can effectively be recognised by microsatellite
instability (MSI) testing. The aim of the present study is to compare the effectiveness of
a MSI test for the identification of Lynch syndrome in patients selected by a pathologist
mainly based on young age at diagnosis (MSI-testing-indicated-by-a-Pathologist; MIPA),
with that of patients selected by a clinical geneticist mainly based on family history
(MSI-testing-indicated-by-Family-History; MIFH).
Patients with a Lynch syndrome associated tumour were selected using MIPA (n = 362) or
MIFH (n = 887). Germline DNA mutation testing was performed in 171 out of 215 patients
(80%) with a MSI positive tumour.
MSI was tested positive in 20% of the MIPA-group group compared to 16% in the MIFH-
group (P = 0.291). In 91 of 171 patients with MSI positive tumours tested for germline muta-
tions were identified as Lynch syndrome patients: 42% in the MIPA-group and 56% in the
MIFH-group (P = 0.066). Colorectal cancer (CRC) or endometrial cancer (EC) presenting at
an age below 50 years would have led to the diagnosis of Lynch syndrome in 89% of these
families (CRC below 50 years: 88% and EC below 50 years: 12%). Families detected by MIPA
were characterised more often by extracolonic Lynch syndrome associated malignancies,
especially EC (P < 0.001).
Our results indicate that recognition of Lynch syndrome by CRC or EC below 50 years is as
effective as a positive family history. Families from patients selected by individual criteria
more often harbour extracolonic Lynch syndrome associated malignancies.
 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Lynch syndrome, previously called Hereditary Non-Polyposis
Colorectal Cancer (HNPCC)1, is the most common type of
hereditary colorectal cancer (CRC) and is caused by a germline
mutation in one of the mismatch repair (MMR) genes.2 Lynch
syndrome accounts for upto 5% of CRCs.3–6 The recognition of
Lynch syndrome is highly relevant, because surveillance sub-
stantially reduces morbidity and mortality in family members
carrying a MMR gene mutation.7,8 Once patients with Lynch
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syndrome are identified, this will lead to identification of
more family members with Lynch syndrome in a highly
cost-effective way.9,10
Tumours that develop as a result of Lynch syndrome can
effectively be recognised by microsatellite instability (MSI)
testing or immunohistochemical analysis of the MMR pro-
teins MLH1, PMS2, MSH2 and MSH6.4,6,9 MSI is a hallmark of
a defective MMR system, which can also be caused by an
acquired non-hereditary hypermethylation of the MLH1
promoter. This is the main cause of MSI in CRC diagnosed
at relatively high age, but hardly occurs in patients with a
MSI-positive tumour diagnosed before the age of 50.11
Traditionally, patients are included for MSI testing after
referral to a genetic counselling unit (MSI-testing-indicated-
by-Family-History; MIFH) mostly because of occurrence of
multiple CRC in the family (Bethesda criteria). However, by
using family history only a small proportion of the expected
number of patients at risk for Lynch syndrome is identi-
fied.12–15 This is due to small families, unawareness by the pa-
tients of their own family history and suboptimal registration
of family history of cancer by doctors.12–15
To improve recognition of patients with a newly diagnosed
tumour, that is known to be associated with Lynch syndrome,
as being at risk for Lynch syndrome, a new guideline was
developed. In this MSI-testing-indicated-by-a-Pathologist
(MIPA)-procedure9, pathologists initiate MSI testing based on
one of the following criteria, called MIPA criteria: (1) CRC or
endometrial cancer (EC) diagnosed before age 50; (2) second
CRC before age 70; (3) CRC and a Lynch syndrome associated
cancer before age 70; or (4) a colorectal adenoma with high
grade dysplasia before age 40.9,16,17 Pathologists report the
MSI test result to the surgeon or gastroenterologist with the
advice to consider referral for genetic counselling in an outpa-
tient clinic for hereditary cancer if the MSI test was positive.
This new guideline was proven to be feasible, cost-effective
and could easily be implemented.9,18,19
The aim of the present study is to compare the predictive
value of a positive MSI test for the presence of Lynch syn-
drome in newly diagnosed patients selected by a pathologist
based on individual characteristics only (MIPA), to that in pa-
tients who are included for MSI testing by a genetic counsel-
ling unit mainly based on family history (MIFH).
2. Patients and methods
2.1. Patients
The study cohort consisted of patients from the Departments
of Human Genetics and Pathology of the Radboud University
Nijmegen Medical Centre in The Netherlands, who had a MSI
test. A series of 1249 patients with a tumour type known to be
associated with Lynch syndrome (colorectal cancer (n = 1141),
carcinomas of the endometrium (n = 67), ovaries (n = 6), small
bowel (n = 8), stomach (n = 9), sebaceous gland (n = 6), and
upper urinary tract (n = 12)) were prospectively selected for
the current study. The enclosed patients were divided into
two groups: patients with a MSI test indicated by a pathologist
based on individual patient characteristics, the so-called
MIPA-group (n = 362, collected between January 2005 and
November 2009), and patients with a MSI test indicated by a
clinical geneticist predominantly based on family history,
the so called MIFH-group (n = 887, collected between June
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Fig. 1 – The flow of patients following the MIPA-strategy or the MIFH-strategy.
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1997 and November 2009). Data on the underlying defect
causing MMR deficiency were collected until March 2010.
Fig. 1 presents a flow diagram of both methods.
2.2. Analysis of microsatellite instability,
hypermethylation of MLH1 and germline mutations
MSI analysis, immunohistochemistry of MLH1, MSH2, MSH6
and PMS2, analysis of hypermethylation of the MLH1 pro-
moter and mutation analysis of one of the MMR genes were
performed as described previously.11,20 For extracolonic tu-
mours a combination of MSI testing and immunohistochem-
ical analysis was used to minimise the chance of missing a
MMR deficient tumour.
2.3. Statistical analysis
The baseline characteristics in the group selected for MSI
analysis by the pathologists (MIPA-group) based on individual
patient characteristics and in the group included after genetic
counselling (MIFH-group) mainly based on family history was
compared by the use of cross tabs and Student’s t-test for con-
tinuous variables and the Pearson Chi-square test for discrete
variables. When sample sizes were small Fisher’s exact test
was performed.
All computations were donewith the SPSS statistical pack-
age (release 16.0.2, April 2008). Two-sided P-values below 0.05
were considered to be statistically significant.
3. Results
3.1. General characteristics
In total 1249 patients with a tumour type known to be associ-
ated with Lynch syndrome were included in the current study
of whom 1038 were tested negative for MSI and 215 (17%) had
a MSI positive tumour. The mean age at CRC diagnosis was
younger in the MIPA-group, compared to the MIFH-group,
46 ± 10 years and 50 ± 11 years, respectively (P = 0.006). At
least one of the individual MIPA criteria was fulfilled in
100% of the MIPA-group and in only 56% (499/887) of the MIFH
group (P < 0.001). Twenty percent of the patients in the
MIPA-group based on individual characteristics (71/362) and
16% in the MIFH-group based on family history (144/887) were
tested positive for MSI. This difference was not statistically
significant (P = 0.291). The flow of both groups is illustrated
in Fig. 1.
Overall, a majority of 58% patients (724/1249) fulfilled the
MIPA criteria 1: having a CRC or EC diagnosed below 50 years
(CRC below 50: 96% (696/724) and EC below 50: 4% (28/724)).
Very few patients, 4% (56/1291), fulfilled MIPA criterion 3 being
diagnosed with CRC below 70 years with a history of an
extracolonic Lynch associated tumour below 70 years
(n = 45), or MIPA criterion 4 having an adenoma diagnosed
below age 40 years (n = 11). As illustrated in Table 1, the fulfil-
ment of the various MIPA criteria was equally distributed
among the MSI positive and the MSI negative group.
For the MIPA-group 96% of the MSI tests were performed
on CRC (352/362) and 3% on EC (9/362), while in the
MIFH-group 89% was performed on CRC (789/887) and 7% on
EC (58/887). In the MIPA-group less females were index than
in the MIFH-group (48% and 59%, respectively), however, there
was no statistical significant difference (P = 0.272).
In total, 171 pedigrees were available of the patients with a
MSI positive tumour (MIPA-group n = 31 and MIFH-group
n = 140). The characteristics of the pedigrees are summarised
in Table 2. As compared to the MIFH-group patients from the
MIPA-group were less likely to have a family history with two
first degree relatives with a CRC (i.e. with the inclusion of the
index patient; P < 0.001).
In the MIPA-group 69% (9/13) patients identified as having
Lynch syndrome by germline mutation analysis had a family
with at least two first degree relatives with CRC compared to
95% (74/78) in the MIFH-group (P < 0.001). In families of only
four Lynch syndrome patients from the MIPA-group (31%)
and of four Lynch syndrome patients from the MIFH-group
(5%) Lynch syndrome associated tumours other than CRC,
especially EC, were present (P < 0.001). In three of them, a
combination of patients with CRC or EC was present and in
one family only EC’s were diagnosed.
Table 1 – Distribution of MIPA criteria among patients recognised by individual characteristics (MIPA) and by family history
(MIFH).
Microsatellite instability (MSI) positive MSI negative
MIPA MIFH MIPA MIFH
N = 71 N = 144 N = 291 N = 743
Fulfilling one of the MIPA criterion 71 (100%) 90 (63%) 291 (100%) 409 (55%)
Criterion 1:
CRC <50a 45 (63%) 68 (76%) 224 (77%) 359 (88%)
EC <50b 5 (7%) 9 (10%) 3 (1%) 11 (3%)
Criterion 2: second CRC <70a 20 (29%) 5 (5%) 54 (18%) 27 (6%)
Criterion 3: second extracolonic cancer <70c – 7 (8%) 5 (2%) 8 (2%)
Criterion 4: adenoma HDP age <40d 1 (1%) 1 (1%) 5 (2%) 4 (1%)
a CRC: colorectal cancer.
b EC: endometrial cancer.
c Extracolonic cancer: carcinomas of the endometrium, ovaries, small bowel, stomach, sebaceous gland, biliary tract, and upper urinary tract.
d HDP: high grade dysplasia.
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3.2. Outcome of DNA mutation and somatic MLH1
hypermethylation analysis
In Table 3, the results are presented of the analysis of the
underlying cause of the MMR deficiency in 44% (31/71) and
97% (140/144) of the MSI positive patients from the MIPA-
and MIFH-group, respectively. This incompleteness was due
to the fact that not all patients with a MSI positive tumour
in the MIPA-group have visited our genetic counselling unit
yet. Overall, in 91 patients, a pathogenic germline mutation
was found. Such a germline mutation was detected in 42%
of the patients tested in the MIPA-group (13/31) and in 56%
of the patients tested in the MIFH-group (78/140; P = 0.066).
Overall MIPA-criteria were fulfilled in 81% of the mutation-po-
sitive patients (74/91), of whom 89% fulfilled the first MIPA-
criterion (66/74), having had a CRC or EC diagnosed below
50 years (CRC below 50 years: 88% (58/66) and EC below
50 years: 12% (8/66)). Every patient in the MIPA-group with a
positive MSI test in a CRC or EC diagnosed below 50 years
had a probability of 50% having Lynch syndrome and only
12% having a sporadic tumour with somatic MLH1 hyperme-
thylation. In contrast every patient in the MIPA-group with a
positive MSI test in a second CRC had a probability of only
15% having Lynch syndrome and 70% having a sporadic tu-
mour with MLH1 hypermethylation.
Overall, hypermethylation was present in approximately a
quarter of the MSI-positive tumours from both groups, pre-
dominantly from patients with either two CRC’s or a CRC
and a second extracolonic Lynch associated tumour. The
overall results are illustrated in Fig. 2, and show that 9% of
all patients in both the MIPA- and the MIFH-group Lynch syn-
drome was diagnosed.
3.3. Characteristics of patients with unexplained MSI and
their families
Both in the MIPA- and in the MIFH-group a substantial num-
ber of patients with a MSI positive tumour could not be ex-
plained by the presence of a mutation in one of the MMR
genes or somatic hypermethylation of the MLH1 promoter.
Overall, 42 of these patients with unexplained MSI were
identified.
In Table 4 individual and family characteristics of Lynch
syndrome and patients with unexplained MSI are compared.
Both the mean age at onset of the index patients (44 and
49 years, P < 0.05) and the mean age at diagnosis of the two
Table 2 – Family characteristics of patients recognised by individual characteristics (MIPA-group) or family history (MIFH-
group) (family characteristics are given of those patients who had a germline DNA mutation analysis).
Characteristics MIPA-group MIFH-group P-value
N = 31c N = 140d
Fulfilled the Amsterdam I criteria 8 (26%) 36 (25%) nse
Fulfilled the Amsterdam II criteria 10 (32%) 60 (42%) nse
Fulfilled revised Bethesda criteria 29 (94%) 120 (83%) nse
Two first degree relatives with CRCa 14 (45%) 104 (74%) <0.001f
Two first degree relatives with Lynch syndrome associated cancer one under 50b 14 (45%) 76 (53%) nse
Mean age of two youngest relatives with Lynch syndrome associated cancerb 49 ± 11 46 ± 11 nse
a CRC: colorectal cancer.
b Lynch syndrome associated cancer: colorectal cancer, carcinomas of the endometrium, ovaries, small bowel, stomach, sebaceous gland,
biliary tract, and upper urinary tract.
c Only 31/71 patients tested positive in the PA-lab of the RUNMC were referred for genetic counselling at the RUNMC.
d Only 140/144 patients with MSI positive tumour were actually tested.
e ns: Not statistically significant.
f Pearson Chi-square test.
Table 3 – MSI positive and DNA germline mutation tested.
Lynch syndrome Unexplained MSI Hypermethylation
MIPA MIFH MIPA MIFH MIPA MIFH
Number of patientsa 13 78 10 32 8 30
Fulfilling one of the MIPA criteria 13 (100%) 61 (78%) 10 (100%) 19 (59%) 8 (100%) 8 (27%)
Criterion 1: CRC <50b 11 (84%) 47 (77%) 8 (80%) 17 (90%) 3 (38%) 4 (50%)
EC <50c 1 (8%) 7 (12%) 1 (10%) 1 (5%) – –
Criterion 2: second CRC <70b 1 (8%) 2 (3%) 1 (10%) 1 (5%) 5 (62%) 2 (25%)
Criterion 3: second extracolonic cancer <70d – 5 (8%) – – – 2 (25%)
Criterion 4: adenoma HDP age <40e – – – – – –
a MIPA-group: only 31/71 patients tested positive in the PA-lab of the RUNMC were referred for genetic counselling at the RUNMC/MIFH-group:
only 140/144 patients with MSI positive tumour were actually tested.
b CRC: colorectal cancer.
c EC: endometrial cancer.
d Extracolonic cancer: carcinomas of the endometrium, ovaries, small bowel, stomach, sebaceous gland, biliary tract, and upper urinary tract.
e HDP: high grade dysplasia.
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youngest relatives (38 and 46 years, P < 0.001) were lower in
the Lynch syndrome group in comparison to the unexplained
MSI group. In 89% of the families from the Lynch syndrome
group at least two familymemberswere diagnosedwith Lynch
syndrome associated cancer (81/91) compared to 52% of the
families from the patients with an unexplained MSI (22/42).
The clinical Amsterdam II criteria were met in 60% of Lynch
syndrome and 14% of patients with unexplained MSI
(P < 0.001).
4. Discussion
To our knowledge this is the first study among patients with a
Lynch syndrome associated tumour showing that selection of
Table 4 – Individual and family characteristics of Lynch syndrome and patients with unexplained MSI.
MSI positive and
DNA germline
mutation detected
MSI positive,
no hypermethylation and
no DNA germline mutation
detected (‘‘unexplained MSI’’)
P-value
N = 91 N = 42
Age at diagnosis of MSI positive index tumour 44 ± 10 49 ± 11 0.013d
Second Lynch syndrome associated cancers of index patienta 26 (29%) 9 (22%) nse
Age at diagnosis of first Lynch syndrome associated cancer of
index patienta
43 ± 10 48 ± 9 0.007d
Mean age of two youngest relatives with Lynch syndrome
associated cancera,b
38 ± 9 46 ± 11 <0.001d
Fulfilled Amsterdam II criteria 55 (60%) 6 (14%) <0.001f
Fulfilled Bethesda criteria 78 (86%) 35 (83%) nse
Criterion 1 – one patient CRC < 50 yearsc 60 (66%) 23 (54%) nse
Criterion 2 – one patient multiple Lynch syndrome associated
cancersa
31 (34%) 12 (29%) nse
Criterion 4 – CRC plus at least one first degree relative with
Lynch syndrome associated cancer; one
patient < 50 yearsa,c
59 (65%) 8 (19%) <0.001f
Criterion 5 – CRC plus at least two first or second degree
relatives with Lynch syndrome associated
cancera,c
60 (66%) 13 (31%) <0.001f
a Lynch syndrome associated cancer: colorectal cancer, carcinomas of the endometrium, ovaries, small bowel, stomach, sebaceous gland,
biliary tract, and upper urinary tract.
b Lynch syndrome: only 81/91 of the families had at least two family members diagnosed with Lynch syndrome associated cancer/unexplained
MSI: only 22/42 of the families had at least two family members diagnosed with Lynch syndrome associated cancer.
c CRC: colorectal cancer.
d Student’s t-test.
e ns: Not statistically significant.
f Pearson Chi-square test.
Fig. 2 – Outcome of the MIPA-method and the MIFH-method.
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families at risk for Lynch syndrome based on young age at
diagnosis is as effective as selection based on family history.
These two strategies select slightly different families, for
example more families with extracolonic CRC’s were found
by the MIPA-strategy based on young age. Most likely these
two strategies are complementary. Most Lynch syndrome
families, carrying mutations in MMR deficiency genes,
were found in the group of patients diagnosed with CRC
below age 50 years whereas a MSI positive tumour in older pa-
tients with a second CRC or extracolonic Lynch syndrome
associated cancer, was most often explained by somatic
hypermethylation of the MLH1 promoter, and, therefore, spo-
radic and not hereditary by origin. This study thus shows that
the detection of Lynch syndrome facilitated by MSI testing at
the initiative of a pathologist, which is mainly based on young
age at CRC diagnosis, is an excellent adjunct to family history
taking. The conclusion drawn from these data is that MSI
testing by pathologists can improve the identification of
Lynch syndrome in an easy way and will lead to the recogni-
tion of families that are not easily picked up by family history.
Especially families with the presence of extracolonic Lynch
associated cancers, such as EC, ovarian cancer, gastric cancer,
urinary tract cancer and small bowel cancer, are easily over-
looked by their family history.
Both the MIPA- and the MIFH-strategies have advantages
and disadvantages. The MIPA-procedure, easy to apply in dai-
ly clinical practice, is found to be effective and efficient9 and
an electronic reminder system can be used for the identifica-
tion of the eligible patients.21 However, not all involved clini-
cians are being well prepared and informed about the MIPA-
procedure. The main advantages of the MIFH-strategy are
the selection of patients who were diagnosed with a Lynch
associated tumour in the past or who are from a family with
remarkable familial clustering. However, by using family his-
tory only a small proportion of the expected number of pa-
tients at risk for Lynch syndrome is identified due to small
families, unawareness by the patients of their own family his-
tory and suboptimal registration of family history of cancer by
doctors.12–15
Age below 50 years at diagnosis also appeared by far the
most prevalently fulfilled MIPA criterion, and the criterion
that led most often to the diagnosis of Lynch syndrome.
Restriction of the MIPA criteria to one single criterion of age
below 50 years, in our population would have led to the recog-
nition of 90% of the families with Lynch syndrome. Further
studies are needed to examine which age limit is optimal to
detect Lynch syndrome regarding cost effectiveness and fea-
sibility. A restriction of the MIPA criteria to one criterion i.e.
young age at diagnosis only, for example age below 50 years,
may be more easily applied by pathologists and remembered
by surgeons, gastroenterologist and patients.
A substantial group of patients with a positive MSI test
could not be explained by a mutation or by hypermethylation.
The origin of CRC in this group of patients is still unknown.
The first-degree relatives of such patients are counselled to
follow exactly the same surveillance programme as a patient
with Lynch syndrome. However, cancer risk may not be quite
as high as in Lynch families since the number of involved
family members is low, and mean age at diagnosis is higher
in our data.
The most important hurdle for diagnosing Lynch syn-
drome appears to be referral of patients with a positive
MSI test for genetic counselling and DNA testing. In the
present study, 71 patients in the MIPA-group had a MSI po-
sitive tumour, though; only 41% visited our genetic counsel-
ling unit for further genetic testing. Although some patients
might have visited other genetic counselling units, close to
60% of the patients with a MSI positive tumour in the
MIPA-group has not been counselled. Reasons to refrain
from genetic counselling or DNA testing may be personal
reasons including psychosocial, medical or financial conse-
quences and a lack of adequate information. But this may
also be caused by selection bias, i.e. clinicians may only re-
fer patients with a Lynch syndrome associated MSI positive
tumour that also have a positive family history for genetic
testing. In the present study, 69% of MSI positive patients
from the MIPA-group who were referred for genetic testing
actually had a positive family history. Previous studies
showed that only 12–30% of CRC patients with a high famil-
ial risk is referred for genetic counselling.13,22–26 Although
improvement of referral is necessary for both the MIPA-
and the MIFH-procedures, patients seem to be more moti-
vated to visit a clinical genetic centre when MSI was tested
positive (41%) compared to being positive for the Bethesda
criteria (12–30%).
Our group investigated the feelings of patients on genetic
testing offered directly after the diagnosis of colorectal can-
cer, which actually is the case in MIPA. The opinion of CRC pa-
tients was that the advantages of genetic testing weights-up
against the disadvantages. Most of them had wondered why
they had got CRC and whether their children were at risk,
long before their surgeon had offered genetic counselling.27
Previous studies by others showed that mutation carriers
are able to cope with having a germline mutation on the short
as well as on the long term.28–32
In conclusion, our study shows that the identification of
Lynch syndrome facilitated by testing for MSI in CRC diag-
nosed at young age is as effective as MSI-testing based on a
positive family history. The families recognised by young
age at CRC diagnosis are more often characterised by extraco-
lonic Lynch syndrome associated cancers, than those recogni-
sed by family history.
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